Get the Stockscreener App
7.06
12.62%
-1.02
After Hours:
7.14
0.08
+1.13%
Unicycive Therapeutics Inc stock is traded at $7.06, with a volume of 1.63M.
It is down -12.62% in the last 24 hours and down -3.16% over the past month.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
See More
Previous Close:
$8.08
Open:
$8.24
24h Volume:
1.63M
Relative Volume:
2.99
Market Cap:
$188.50M
Revenue:
$675.00K
Net Income/Loss:
$-26.62M
P/E Ratio:
-4.496
EPS:
-1.5703
Net Cash Flow:
$-31.34M
1W Performance:
-8.67%
1M Performance:
-3.16%
6M Performance:
+12.06%
1Y Performance:
+1,176%
1-Day Range:
$6.984
$8.40
1-Week Range:
$6.984
$8.40
52-Week Range:
$0.47
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
7.06 | 215.74M | 675.00K | -26.62M | -31.34M | -1.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Unicycive Therapeutics (UNCY) Surges 5.9% as Shares Test Key ResistanceDemand Zone - Newser
UNCY News | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - ChartMill
Unicycive Therapeutics (UNCY) CEO receives 762,200 restricted stock units award - Stock Titan
Unicycive Therapeutics (UNCY) director granted 126,300 RSUs as equity pay - Stock Titan
Unicycive CEO left clinical medicine to develop kidney disease therapies - The Business Journals
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside - Seeking Alpha
Unicycive (NASDAQ: UNCY) EVP receives 169,500 RSUs as stock award - Stock Titan
Unicycive (UNCY) EVP receives 169,500 RSUs vesting over 3 years - Stock Titan
Unicycive (UNCY) CFO receives 169,500 restricted stock units as equity pay - Stock Titan
UNCY Stock Chart | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - ChartMill
Unicycive Therapeutics (UNCY) Drops -4.29% — Key Support at $7.41 2026-05-19Risk Analysis - Newser
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Unicycive Therapeutics (UNCY) price target decreased by 23.53% to 32.20 - MSN
Unicycive (UNCY) director Sandeep Laumas granted two new RSU awards - Stock Titan
RA Capital affiliates hold 2.80M shares in Unicycive (UNCY) under 9.99% blocker - Stock Titan
TradingKey - TradingKey
Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing? - Yahoo Finance
Unicycive Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Noble Financial Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Guggenheim lowers Unicycive stock price target on higher costs By Investing.com - Investing.com Canada
Guggenheim Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Unicycive Therapeutics stock (US90467V1098): Q1 2026 results and PDUFA update - AD HOC NEWS
Unicycive Therapeutics Reports Q1 2026 Financial Results, FDA Review Progress for Oxylanthanum Carbonate NDA, and Commercial Launch Preparations - Minichart
Unicycive Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Unicycive (NASDAQ: UNCY) Q1 2026 loss deepens as warrant liability swings - Stock Titan
Unicycive Therapeutics Q1 net loss widens on warrant liability - TradingView
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Unicycive Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Unicycive Therapeutics: Runway To Fund Planned Operations Into 2027 >UNCY - Moomoo
Unicycive Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
How Unicycive Therapeutics (UNCY) builds value over time (Dips) 2026-05-08Social Signal Watchlist - Newser
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Unicycive Therapeutics : May 2026 Corporate Presentation - marketscreener.com
Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
B. Riley Initiates Unicycive Therapeutics at Buy With $22 Price Target - Moomoo
B. Riley Financial Begins Coverage on Unicycive Therapeutics (NASDAQ:UNCY) - MarketBeat
B. Riley Securities initiated coverage on Unicycive Therapeutics with a new price target - Quantisnow
UNCY SEC FilingsUnicycive Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Unicycive Therapeutics, Inc. SEC Filing - Stock Titan
Unicycive (NASDAQ: UNCY) outlines 2026 vote, board changes and executive pay - Stock Titan
UNCY Unicycive Therapeutics reports wide Q4 2025 EPS miss, shares dip slightly amid soft investor sentiment.Low Growth - newser.com
UNCY Forecast, Price Target & Analyst Ratings | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - ChartMill
Unicycive Therapeutics (UNCY) Stock: Is It Worth Allocating Capital | Q4 2025: EPS Misses EstimatesEarnings Risk - newser.com
UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval - Stocktwits
UNCY Stock Price, Quote & Chart | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - ChartMill
Unicycive Therapeutics (UNCY) Stock: Why Profit Growth (Edges Up) 2026-04-20Professional Trade Ideas - Xã Thanh Hà
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Connect - ACCESS Newswire
Is Unicycive Therapeutics (UNCY) stock trading at fair value (Drifts Higher) 2026-04-18Stock Accumulation - newser.com
UNCY Options Volatility — NASDAQ:UNCY - TradingView
UNCY Options Chain — NASDAQ:UNCY - TradingView
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):